Carcinoma, Medullary: all 66 studies
Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingNCT07863765Phase 2
- Stromal Desmoplastic Reaction as a Predictive Factor for Lymph Node Metastasis in Medullary Thyroid CancerNot yet recruitingNCT07851324
- Thyroid Health Outcomes Registry for SurgeryNot yet recruitingNCT07812779
- Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaEnrolling by invitationNCT07713901
- 211At-MABG in Adults With Advanced Neuroendocrine CancersNot yet recruitingNCT07661420Phase 1
- Study of SNH-118110 in Advanced Solid TumorsNot yet recruitingNCT07649200Phase 1
- A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNot yet recruitingNCT07621146
- STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck DissectionNot yet recruitingNCT07612293Not applicable
- CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTCRecruitingNCT07383246Phase 3
- Cultural Adaptation of an Educational Tool in Medullary Thyroid CancerRecruitingNCT07142005
- Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTCRecruitingNCT07138716Not applicable
- A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene MutationsNot yet recruitingNCT07048964
- Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsRecruitingNCT07006727Phase 1
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingNCT06814496Phase 1/2
- Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)RecruitingNCT06141369Not applicable
- Natural History of Medullary Thyroid Cancer to Inform Advanced Disease ManagementRecruitingNCT04216732
- Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their CaregiversRecruitingNCT03892993Not applicable
- Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsCompletedNCT04537715Phase 1Results posted
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
- A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationActive, not recruitingNCT04280081Phase 2Results posted
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerActive, not recruitingNCT04211337Phase 3Results posted
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/2Results posted
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
- A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaCompletedNCT02601950Phase 2Results posted
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive CancerActive, not recruitingNCT02293954Not applicableResults posted
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerActive, not recruitingNCT01896479Phase 4Results posted
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney CancerCompletedNCT01767636Phase 2Results posted
- Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid TumorsCompletedNCT01709435Phase 1Results posted
- To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid CancerCompletedNCT01496313Phase 4Results posted
- Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib TreatmentCompletedNCT01298323Phase 3Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
- Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid CancerCompletedNCT00519896Phase 2Results posted
- An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerCompletedNCT00410761Phase 3Results posted
- Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerCompletedNCT00390325Phase 2Results posted
- Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by SurgeryCompletedNCT00381641Phase 2Results posted
- A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerCompletedNCT00358956Phase 2Results posted
- Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2Results posted
- Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid CancerCompletedNCT00118248Phase 2Results posted
- Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer SurvivorsActive, not recruitingNCT07259304
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 1
- Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?CompletedNCT06243965
- European Multicenter Study on Surgical Management of Advanced Thyroid CancerStatus unknownNCT05796960
- Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid CancerCompletedNCT05534594Not applicable
- Medullary Colonic CarcinomaCompletedNCT05184153
- GFRα4 CAR T Cells in MTC PatientsActive, not recruitingNCT04877613Phase 1
- Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 2
- Thermal Ablation of Cervical Metastases From Thyroid CarcinomaCompletedNCT04522570Not applicable
- Cancer and Blood Pressure Management, CARISMA StudyActive, not recruitingNCT04467021Not applicable
- Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine CancersWithdrawnNCT04106843Phase 2
- Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort StudyCompletedNCT03774862
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual ThyrocalcitoninCompletedNCT02856347Not applicable
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorWithdrawnNCT02831179Phase 1
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicable
- 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.Active, not recruitingNCT02088645Phase 1
- Natural History Study of Children and Adults With Medullary Thyroid CancerActive, not recruitingNCT01660984
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT01155258Phase 1
- Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
- Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid CancerTerminatedNCT00647140Phase 2
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
- Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
- Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00027820Phase 1/2
- Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1